Wolf-K Hofmann

Wolf-K Hofmann

Auto-generated profile, based on publicly available information

Wolf-K Hofmann

Department of Hematology, Oncology and Transfusion Medicine, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2005 in Annual Review of Medicine
Verified
Journal Article
Closed access
WHWolf-K. Hofmann
Wolf-K. Hofmann
HKH. Phillip Koeffler
H. Phillip Koeffler
During the past 15 years, important progress has been made in the understanding of the biology and prognosis of myelodysplastic syndrome (MDS). MDS is a clonal disorder characterized by ineffective hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemia (AML). Risk-adapted treatment strategies were established because of the high median age (60–75 years) of the MDS patients and the individual history of the disease (number of cytopenias, cytogenetic changes, transfusion requirements). Allogeneic bone marrow transplantation currently offers the only potentially curative treatment, but this form of therapy is not available for the typical MDS patient, who is >60 years of age. Therapy with erythropoietin and G-CSF has improved the quality of life of selected patients. The development of small molecules directed against specific molecular targets with minimal adverse effects is the hope for the future. Innovative uses of immunomodulatory agents and the optimizing of cytotoxic treatment should continue to help in the treatment of MDS.

15 March 2002 in Blood
Verified
Journal Article
Closed access
PDF file
LJLetetia C. Jones
Letetia C. Jones
MLMeng-Liang Lin
Meng-Liang Lin
Shih-Shun ChenShih-Shun Chen
Shih-Shun Chen
UKUtz Krug
Utz Krug
WHWolf-K. Hofmann
Wolf-K. Hofmann
HKH. Phillip Koeffler
H. Phillip Koeffler
CCAAT/enhancer-binding proteins (C/EBPs) are critical transcriptional regulators of differentiation of hematopoietic cells. Previous studies have shown that targeted disruption of theC/ebpα gene results in a lack of granulocytic differentiation with an arrest at the stage of immature myeloblasts. By using a gene replacement strategy in which C/EBPβ was expressed from the C/ebpα gene locus of C/EBPα-null mice, we have evaluated the ability of C/EBPβ to function for C/EBPα in directing differentiation along the granulocytic pathway. We show that the morphology and the differential cell counts of the bone marrow and peripheral blood cells from C/EBPβ knockin mice are indistinguishable from those of their wild-type littermates, indicating that hematopoiesis occurs normally in these animals. Additionally, we analyzed expression of 21 myeloid-specific genes, including markers for distinct stages of granulocytic differentiation, and found no significant differences in their levels of expression in the bone marrow of C/EBPβ knockin and wild-type mice. These results imply that C/EBPβ can substitute for C/EBPα during hematopoiesis when expressed from the C/ebpα gene locus.

1 September 2005 in Stem Cells
Verified
Journal Article
Open access
PDF file
MKMartina Komor
Martina Komor
SGSaskia Güller
Saskia Güller
CBClaudia D. Baldus
Claudia D. Baldus
SVSven de Vos
Sven de Vos
DHDieter Hoelzer
Dieter Hoelzer
WHWolf‐K. Hofmann
Wolf‐K. Hofmann
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. STEM CELLS is read and written by clinical and basic scientists whose expertise encompasses the rapidly expanding fields of stem and progenitor cell biology. STEM CELLS welcomes original articles and concise reviews describing basic laboratory investigations of stem cells and the translation of their clinical aspects of characterization and manipulation from the bench to patient care. The journal covers all aspects of stem cells embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; stem cell technology: epigenetics, genomics, proteomics, and metabonomics; cancer stem cells; translational and clinical research; and regenerative medicine.

31 March 2009 in Leukemia Research
Verified
Journal Article
Closed access
PDF file
OHOlaf Hopfer
Olaf Hopfer
MKMartina Komor
Martina Komor
IKIna Sabine Koehler
Ina Sabine Koehler
CFClaudia Freitag
Claudia Freitag
MSMatthias B. Schulze
Matthias B. Schulze
WHWolf-Karsten Hofmann
Wolf-Karsten Hofmann

1 November 2006 in Leukemia Research
Verified
Journal Article
Closed access
WHW.-K. Hofmann
W.-K. Hofmann
STS. Takeuchi
S. Takeuchi
NTN. Takeuchi
N. Takeuchi
ETE. Thiel
E. Thiel
DHD. Hoelzer
D. Hoelzer
HKH.P. Koeffler
H.P. Koeffler

15 January 2009 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
GHGero Hütter
Gero Hütter
ALAnne Letsch
Anne Letsch
DNDaniel Nowak
Daniel Nowak
JPJulia Poland
Julia Poland
PSPranav Sinha
Pranav Sinha
WHWolf-K Hofmann
Wolf-K Hofmann
When comparing myelogenous blasts from bone marrow and peripheral blood, immunophenotyping usually show a strong correlation of expression of surface antigens. However, it remains to be determined, whether this correlation also exists on the level of protein expression. Therefore, we investigated both bone marrow and peripheral blood blast cells from six patients with newly diagnosed acute myeloid leukemia (AML) using conventional two-dimensional electrophoresis in the first dimension and linear polyacrylamide gels (12%) in the second dimension. Proteins were visualized using the silver staining method and image analysis was performed using the PDQuest system. For each patient over 80 proteins were evaluated in the sample from peripheral blood and bone marrow. We could demonstrate that the protein expression profile of bone marrow did not significantly differ from the expression patterns of peripheral blast cells. The proteome-set of leukemic blast cells from marrow and blood, does not differ substantially when drawn from AML patients with over 80 percent blast cells in both compartments. This indicates that in AML, blasts from peripheral blood samples can be considered suitable for investigations of the proteome using 2D-electrophoresis.